97 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
in the Majority of Ovarian Cancers HGSOC samples from an ongoing azenosertib clinical trial (ZN-c3-002, N=111) as well as 56 procured samples Cyclin E1 H
S-3ASR
EX-4.3
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
of a majority in principal amount of the outstanding Securities of that Series, by written notice to the Company and the Trustee, may rescind and annul … to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Securities of that Series;
it being
S-3ASR
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders … for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. We have no present
8-K
EX-3.1
cum4agpwxll593152nx
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm
8-K
EX-99.2
gsl t0n1rbsdq2pbhdrk
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
hc5a1
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
gy8u3592bv4cp
9 Aug 23
Regulation FD Disclosure
4:15pm
424B5
q96hp
15 Jun 23
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.3
t0fmnv8e
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
wbt fl2dwvtq4g6ureh
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.1
9w647q5baxb1o9
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am